Rapid Micro Biosystems (RPID) 10-Q 3 May 24 2024 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2024	Apr. 30, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-40592
Entity Registrant Name	Rapid Micro Biosystems, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-8121647
Entity Address, Address Line One	1001 Pawtucket Boulevard West
Entity Address, Address Line Two	Suite 280
Entity Address, City or Town	Lowell
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01854
City Area Code	978
Local Phone Number	349-3200
Title of 12(b) Security	Class A common stock, $0.01 par value per share
Trading Symbol	RPID
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Central Index Key	0001380106
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false
Class A Common stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		37,552,287
Class B Common stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		5,309,529

Condensed consolidated balance

Condensed consolidated balance sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 22,433	$ 24,285
Short-term investments	57,103	67,768
Accounts receivable	4,921	5,532
Inventory	20,418	19,961
Prepaid expenses and other current assets	3,285	2,869
Total current assets	108,160	120,415
Property and equipment, net	12,615	12,832
Right-of-use assets, net	5,988	6,240
Long-term investments	0	2,911
Other long-term assets	684	770
Restricted cash	284	284
Total assets	127,731	143,452
Current liabilities:
Accounts payable	1,164	1,973
Accrued expenses and other current liabilities	7,049	9,907
Deferred revenue	6,234	5,974
Lease liabilities, short-term	1,153	1,132
Total current liabilities	15,600	18,986
Lease liabilities, long-term	5,916	6,214
Other long-term liabilities	272	263
Total liabilities	21,788	25,463
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $0.01 par value: 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	547,300	546,051
Accumulated deficit	(441,707)	(428,385)
Accumulated other comprehensive loss	(78)	(101)
Total stockholders’ equity	105,943	117,989
Total liabilities and stockholders’ equity	127,731	143,452
Class A Common stock
Stockholders’ equity:
Common stock	375	371
Class B Common stock
Stockholders’ equity:
Common stock	$ 53	$ 53

Condensed consolidated balanc_2

Condensed consolidated balance sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Class A Common stock
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	210,000,000	210,000,000
Common stock, issued (in shares)	37,483,559	37,099,909
Common stock, outstanding (in shares)	37,483,559	37,099,909
Class B Common stock
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	10,000,000	10,000,000
Common stock, issued (in shares)	5,309,529	5,309,529
Common stock, outstanding (in shares)	5,309,529	5,309,529

Condensed consolidated statemen

Condensed consolidated statements of operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 5,611	$ 5,035
Costs and operating expenses:
Research and development	3,842	3,153
Sales and marketing	3,281	3,462
General and administrative	5,627	6,467
Total costs and operating expenses	19,884	19,907
Loss from operations	(14,273)	(14,872)
Other income (expense):
Interest income, net	983	1,003
Other expense, net	(29)	(11)
Total other income, net	954	992
Loss before income taxes	(13,319)	(13,880)
Income tax expense	3	7
Net loss	$ (13,322)	$ (13,887)
Net loss per share - basic (in dollars per share)	$ (0.31)	$ (0.32)
Net loss per share - diluted (in dollars per share)	$ (0.31)	$ (0.32)
Weighted average common shares outstanding - basic (in shares)	43,245,835	42,812,580
Weighted average common shares outstanding - diluted (in shares)	43,245,835	42,812,580
Product
Revenue:
Total revenue	$ 3,713	$ 3,324
Costs and operating expenses:
Cost of revenue	5,173	4,981
Service
Revenue:
Total revenue	1,898	1,711
Costs and operating expenses:
Cost of revenue	$ 1,961	$ 1,844

Condensed consolidated statem_2

Condensed consolidated statements of comprehensive loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (13,322)	$ (13,887)
Other comprehensive income:
Unrealized gain on investments, net of tax	23	447
Comprehensive loss	$ (13,299)	$ (13,440)

Condensed consolidated statem_3

Condensed consolidated statements of stockholders' equity - USD ($) $ in Thousands	Total	Class A Common stock	Class B Common stock	Common stock Class A Common stock	Common stock Class B Common stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive loss
Balance at beginning of period (in shares) at Dec. 31, 2022				36,538,805	5,553,379
Balance at beginning of period at Dec. 31, 2022	$ 164,169			$ 366	$ 55	$ 540,775	$ (375,918)	$ (1,109)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock under ESPP (in shares)				125,536
Issuance of Class A common stock under ESPP	124			$ 1		123
Vesting of restricted stock units (in shares)				96,303
Vesting of restricted stock units	0			$ 1		(1)
Restricted stock award liability accretion	341					341
Issuance of Class A common stock upon exercise of common stock options (in shares)				7,896
Issuance of Class A common stock upon exercise of common stock options	6					6
Stock-based compensation expense	1,243					1,243
Net loss	(13,887)						(13,887)
Other comprehensive income	447							447
Balance at end of period (in shares) at Mar. 31, 2023				36,768,540	5,553,379
Balance at end of period at Mar. 31, 2023	152,443			$ 368	$ 55	542,487	(389,805)	(662)
Balance at beginning of period (in shares) at Dec. 31, 2023		37,099,909	5,309,529	37,099,909	5,309,529
Balance at beginning of period at Dec. 31, 2023	117,989			$ 371	$ 53	546,051	(428,385)	(101)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock under ESPP (in shares)				198,299
Issuance of Class A common stock under ESPP	168			$ 2		166
Vesting of restricted stock units (in shares)				185,331
Vesting of restricted stock units	$ 0			$ 2		(2)
Issuance of Class A common stock upon exercise of common stock options (in shares)	20			20
Stock-based compensation expense	$ 1,085					1,085
Net loss	(13,322)						(13,322)
Other comprehensive income	23							23
Balance at end of period (in shares) at Mar. 31, 2024		37,483,559	5,309,529	37,483,559	5,309,529
Balance at end of period at Mar. 31, 2024	$ 105,943			$ 375	$ 53	$ 547,300	$ (441,707)	$ (78)

Condensed consolidated statem_4

Condensed consolidated statements of cash flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (13,322)	$ (13,887)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	806	759
Stock-based compensation expense	1,085	1,243
Provision for excess and obsolete inventory	85	34
Noncash lease expense	305	297
Accretion on investments	(500)	(586)
Other	8	9
Changes in operating assets and liabilities:
Accounts receivable	611	(142)
Inventory	(543)	209
Prepaid expenses and other current assets	(415)	367
Other long-term assets	0	(23)
Accounts payable	(809)	(4,141)
Accrued expenses and other current liabilities	(3,095)	(1,615)
Deferred revenue	259	790
Net cash used in operating activities	(15,525)	(16,686)
Cash flows from investing activities:
Purchases of property and equipment	(585)	(759)
Purchases of investments	(4,380)	(17,831)
Maturity of investments	18,480	32,500
Net cash provided by investing activities	13,515	13,910
Cash flows from financing activities:
Proceeds from issuance of Class A common stock - stock option exercise	0	7
Proceeds from issuance of Class A common stock - employee stock purchase plan	168	124
Payments on finance lease obligations	(10)	(9)
Net cash provided by financing activities	158	122
Net decrease in cash, cash equivalents and restricted cash	(1,852)	(2,654)
Cash, cash equivalents and restricted cash at beginning of period	24,569	27,348
Cash, cash equivalents and restricted cash at end of period	22,717	24,694
Supplemental disclosure of cash flow information
Cash paid for interest	9	10
Supplemental disclosure of non-cash investing activities
Purchases of property and equipment in accounts payable and accrued expenses	$ 348	$ 154

Nature of the business and basi

Nature of the business and basis of presentation	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the business and basis of presentation	Nature of the business and basis of presentation Rapid Micro Biosystems, Inc. (the “Company”) was incorporated under the laws of the State of Delaware on December 29, 2006. The Company develops, manufactures, markets and sells Growth Direct systems (“Systems”) proprietary consumables, laboratory information management system (“LIMS”) connection software, and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices and personal care products. The Company’s technology uses a highly sensitive camera and the natural auto fluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The Company currently sells to customers in North America, Europe and the Asia-Pacific region. The Company is headquartered in Lowell, Massachusetts. Basis of presentation These condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries in Germany and Switzerland. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s audited consolidated financial statements for the year ended December 31, 2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2024 and the results of its operations and its cash flows for the three months ended March 31, 2024 and 2023. The financial data and other information disclosed in these notes related to the three months ended March 31, 2024 and 2023 are also unaudited. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period. Liquidity The Company has incurred recurring losses and net cash outflows from operations since its inception. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its existing cash and cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months following the date these unaudited interim condensed consolidated financial statements were issued.

Summary of significant accounti

Summary of significant accounting policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, calculating the standalone selling price for revenue recognition, the valuation of inventory, and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific and relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. There have been no significant changes to the Company's significant accounting policies during the three months ended March 31, 2024, as compared to those disclosed in Note 2 of the audited consolidated financial statements as of December 31, 2023 filed with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Risk of concentrations of credit, significant customers and significant suppliers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments and accounts receivable. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash and cash equivalents and investments with financial institutions that management believes to be of high credit quality. The Company has not experienced any other-than-temporary losses with respect to its cash equivalents and investments and does not believe that it is subject to unusual credit risk beyond the credit risk associated with commercial banking relationships. Significant customers are those which represent more than 10% of the Company’s total revenue or accounts receivable balance at each respective balance sheet date. The following table presents customers that represented 10% or more of the Company’s total revenue: Three Months Ended March 31, 2024 2023 Customer A 19.4 % 20.1 % Customer B 14.3 % 27.0 % 33.7 % 47.1 % The following table presents customers that represented 10% or more of the Company’s accounts receivable: March 31, December 31, 2024 2023 Customer B 41.9 % 16.4 % Customer A 13.5 % 10.7 % Customer C * 21.4 % Customer D * 12.4 % 55.4 % 60.9 % ____________________________ * – less than 10% The Company relies on third parties for the supply and manufacture of certain components of its products as well as third-party logistics providers. There were no significant concentrations around a single third-party supplier, manufacturer, or logistics provider for the three months ended March 31, 2024 or 2023. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. At both March 31, 2024 and December 31, 2023, the Company held cash of $0.1 million in banks located outside of the United States. Restricted cash As of both March 31, 2024 and December 31, 2023, the Company was required to maintain guaranteed investment certificates of $0.3 million with maturities of three months to one year that are subject to an insignificant risk of changes in value. The guaranteed investment certificates are held for the benefit of the landlord in connection with operating leases which have remaining terms of greater than one year and are classified as restricted cash (non-current) on the Company’s consolidated balance sheets. Software Development Costs The Company accounts for software development costs for internal-use software under the provisions of ASC 350-40, “Internal-Use Software ” (“ASC 350”). Accordingly, certain costs to develop internal-use computer software are capitalized, provided these costs are expected to be recoverable. There was $1.4 million of software development costs related to the Company's enterprise resource planning ("ERP") system capitalized in other long-term assets at both March 31, 2024 and December 31, 2023, net of accumulated amortization of $0.8 million and $0.7 million, respectively. These capitalized costs are being amortized on a straight-line basis over the initial subscription term of five years. For each of the three months ended March 31, 2024 and 2023, there was $0.1 million of amortization expense related to capitalized software development costs recorded in the condensed consolidated statements of operations. Fair value measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company’s cash equivalents, short-term and long-term investments are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities. Product warranties The Company offers a one-year limited assurance warranty on System sales, which is included in the selling price. The accrual for these warranty obligations is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. The following table presents a summary of changes in the amount reserved for warranty cost (in thousands): Three Months Ended March 31, 2024 2023 Balance, beginning of period $ 689 $ 872 Warranty provisions — — Warranty repairs — (346) Balance, end of period $ 689 $ 526 Segment information The Company determined its operating segment after considering the Company’s organizational structure and the information regularly reviewed and evaluated by the Company’s chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company has determined that its CODM is its Chief Executive Officer. The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. On the basis of these factors, the Company determined that it operates and manages its business as one operating segment, that develops, manufactures, markets and sells Systems and related LIMS connection software, consumables and services; and accordingly has one reportable segment for financial reporting purposes. Substantially all of the Company’s long-lived assets are held in the United States. Revenue recognition Remaining performance obligations The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. The Company does not have material remaining performance obligations associated with contracts with terms greater than one year. Contract balances from contracts with customers Contract assets arise from customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company’s right to payment is conditional and not only subject to the passage of time. The Company had $0.1 million in contract assets as of both March 31, 2024 and December 31, 2023, included in prepaid expenses and other current assets. Contract liabilities represent the Company’s obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. The Company has a contract liability related to service revenue, which consists of amounts that have been invoiced but that have not been recognized as revenue. Amounts expected to be recognized as revenue within 12 months of the balance sheet date are classified as current deferred revenue and amounts expected to be recognized as revenue beyond 12 months of the balance sheet date are classified as non-current deferred revenue. The Company did not record any non-current deferred revenue as of March 31, 2024 or December 31, 2023. Deferred revenue was $6.2 million and $6.0 million at March 31, 2024 and December 31, 2023, respectively. Revenue recognized during the three months ended March 31, 2024 and 2023 that was included in deferred revenue at the prior period-end was $1.4 million and $1.0 million, respectively. Disaggregated revenue The Company disaggregates revenue based on the recurring and non-recurring nature of the underlying sale. Recurring revenue includes sales of consumables and service contracts. The Company considers these to be recurring revenues because customers typically place purchase orders on a periodic basis as they use their Growth Direct system(s) over time. These arrangements typically contain a single performance obligation and thus the entire consideration to which the Company is entitled is allocated entirely to that performance obligation. Non-recurring revenue includes sales of systems, LIMS connection software, validation services, and field services, and typically contains multiple performance obligations. The Company considers these to be non-recurring revenues because customers typically place single purchase orders for a bundle of products and services on a one-time or infrequent basis. For these arrangements, significant judgment is applied in identifying the distinct performance obligations, determination of the transaction price, transaction price allocation, and determination of standalone selling price for each of the distinct performance obligations. The following table presents the Company’s revenue by the recurring or non-recurring nature of the revenue stream (in thousands): Three Months Ended March 31, 2024 2023 Product and service revenue — recurring $ 3,743 $ 3,253 Product and service revenue — non-recurring 1,868 1,782 Total revenue $ 5,611 $ 5,035 The following table presents the Company’s revenue by customer geography (in thousands): Three Months Ended March 31, 2024 2023 United States $ 2,149 $ 1,703 Switzerland 972 973 Japan 800 1,386 Germany 464 413 All other countries 1,226 560 Total revenue $ 5,611 $ 5,035 Advertising costs Advertising costs are expensed as incurred and are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising costs were less than $0.1 million during each of the three months ended March 31, 2024 and 2023. Stock-based compensation The Company measures all stock-based awards granted to employees, officers and directors based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with (i) service-based vesting conditions only and (ii) stock-based awards with both service-based and Company performance vesting conditions, and records the expense for these awards using the straight-line method. Forfeitures are accounted for prospectively as they occur. The Company measures all restricted stock units granted to employees based on the common stock value on the date of grant. The purchase price of the restricted stock is the common stock value on the date of grant. Recently issued accounting pronouncements The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups ("JOBS") Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the newer revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic companies. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. The new standard requires enhanced disclosures about a public entity's reportable segments including more detailed information about a reportable segment's expenses. The amendments in this update apply to all public entities that are required to report segment information, and include those entities that have a single reportable segment. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this update are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.

Fair value of financial assets

Fair value of financial assets and liabilities	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair value of financial assets and liabilities	Fair value of financial assets and liabilities The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands): Fair value measurements as of March 31, 2024 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 19,346 $ — $ — $ 19,346 Short-term investments 52,923 4,180 — 57,103 $ 72,269 $ 4,180 $ — $ 76,449 Fair value measurements as of December 31, 2023 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 20,306 $ — $ — $ 20,306 Short-term investments 62,625 5,143 — 67,768 Long-term investments 2,911 — — 2,911 $ 85,842 $ 5,143 $ — $ 90,985 During the three months ended March 31, 2024 and 2023, there were no transfers in or out of Level 3. Valuation of short-term and long-term investments U.S. Treasury bills and notes included in short-term and long-term investments were valued by the Company using quoted prices in active markets for identical securities, which represents a Level 1 measurement within the fair value hierarchy. The Company's certificates of deposit included in short-term and long-term investments were valued using quoted prices for similar assets in active markets (or identical assets in inactive markets), which represent a Level 2 measurement within the fair value hierarchy.

Investments

Investments	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Short-term and long-term investments by investment type consisted of the following (in thousands): March 31, 2024 Amortized Gross Gross Fair Short-term investments Certificates of Deposit $ 4,192 $ — $ (11) $ 4,181 U.S. Government Treasury Bills 14,795 — (6) 14,789 U.S. Government Treasury Notes 38,194 3 (64) 38,133 $ 57,181 $ 3 $ (81) $ 57,103 December 31, 2023 Amortized Gross Gross Fair Short-term investments Certificates of Deposit $ 5,164 $ — $ (21) $ 5,143 U.S. Government Treasury Bills 16,184 9 — 16,193 U.S. Government Treasury Notes 46,536 42 (146) 46,432 $ 67,884 $ 51 $ (167) $ 67,768 Long-term Investments U.S. Government Treasury Notes - Maturity Up To Two Years 2,896 15 — 2,911 $ 2,896 $ 15 $ — $ 2,911

Inventory

Inventory	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consisted of the following (in thousands): March 31, December 31, 2024 2023 Raw materials $ 11,654 $ 12,873 Work in process 423 150 Finished goods 8,341 6,938 Total $ 20,418 $ 19,961 Raw materials, work in process and finished goods were net of adjustments to net realizable value of $0.7 million and $0.6 million as of March 31, 2024 and December 31, 2023, respectively.

Prepaid expenses and other curr

Prepaid expenses and other current assets	3 Months Ended
	Mar. 31, 2024
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses and other current assets	Prepaid expenses and other current assets Prepaid expenses and other current assets consisted of the following (in thousands): March 31, December 31, 2024 2023 Prepaid insurance $ 803 $ 1,282 Contract asset 94 51 Deposits 742 667 Other receivables 333 137 Prepaid financing fees 295 292 Other 1,018 440 $ 3,285 $ 2,869

Property and equipment, net

Property and equipment, net	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property and equipment, net	Property and equipment, net Property and equipment, net consisted of the following (in thousands): March 31, December 31, 2024 2023 Manufacturing and laboratory equipment $ 13,850 $ 13,750 Computer hardware and software 2,034 1,960 Office furniture and fixtures 589 589 Leasehold improvements 8,995 8,551 Construction-in-process 2,165 2,292 27,633 27,142 Less: Accumulated depreciation (15,018) (14,310) $ 12,615 $ 12,832 Depreciation and amortization expense related to property and equipment was $0.7 million for each of the three months ended March 31, 2024 and 2023.

Accrued expenses and other curr

Accrued expenses and other current liabilities	3 Months Ended
	Mar. 31, 2024
Accrued Liabilities, Current [Abstract]
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): March 31, December 31, 2024 2023 Accrued employee compensation and benefits expense $ 2,779 $ 4,808 Accrued vendor expenses 3,198 4,017 Accrued warranty expense 689 689 Accrued taxes 259 252 Other 124 141 $ 7,049 $ 9,907

Common stock and common stock w

Common stock and common stock warrants	3 Months Ended
	Mar. 31, 2024
Common stock and common stock warrants
Common stock and common stock warrants	Common stock and common stock warrants As of both March 31, 2024 and December 31, 2023, the Company’s restated certificate of incorporation authorized the issuance of Class A and Class B common stock. Each share of Class A common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. The Company’s Class B common stock is non-voting. Class A and Class B common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of Preferred Stock. As of March 31, 2024, no cash dividends had been declared or paid. As of March 31, 2024, the Company had reserved 24,147,346 shares of Class A common stock for the exercise of outstanding stock options and warrants, vesting of restricted stock units, the number of shares remaining available for grant under the Company’s 2021 Incentive Award Plan (see Note 10), the number of shares available for purchase under the Company’s Employee Stock Purchase Plan (see Note 10) and the conversion of Class B common stock. As of both March 31, 2024 and December 31, 2023, outstanding warrants to purchase common stock consisted of the following: Issuance date Contractual term Balance sheet Shares of Weighted average (in years) July 24, 2017 10 Equity 17,194 $ 292.81 April 12, 2018 10 Equity 30,000 $ 1.00 July 14, 2021 * 10 Equity 975,109 $ 1.46 1,022,303 ____________________________ * – In connection with the IPO, preferred stock warrants were automatically converted to Class A common stock warrants. The contractual term of the converted Class A common stock warrants remained consistent with the original term of the preferred stock warrants, with original issue dates between 2017-2020.

Stock-based compensation

Stock-based compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation 2010 Stock Option and Grant Plan The Company’s 2010 Stock Option and Grant Plan (the “2010 Plan”) provided for the Company to grant incentive stock options or nonqualified stock options, restricted stock awards and other stock-based awards to employees, officers, directors and consultants of the Company. Following the effectiveness of the Company's initial public offering ("IPO") in July 2021, no additional awards are being granted under the 2010 Plan and shares of existing outstanding options that were issued under the 2010 Plan and are forfeited or canceled will be available for grant under the 2021 Incentive Award Plan. 2021 Incentive Award Plan In July 2021, the board of directors adopted, and the Company’s stockholders approved, the 2021 Incentive Award Plan (the “2021 Plan”). The 2021 Plan provides for the grant of stock options, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based and cash-based awards. The 2021 Plan has a term of ten years. The aggregate number of shares of Class A common stock available for issuance under the 2021 Plan is equal to the sum of (i) 4,200,000 shares; (ii) any shares which are subject to the 2010 Plan awards that become available for issuance under the 2021 Plan; and (iii) an annual increase for ten years on the first day of each calendar year beginning on January 1, 2022, equal to the lesser of (A) 5% of the aggregate number of shares of Class A common stock outstanding on the last day of the immediately preceding calendar year and (B) such smaller amount of shares as determined by the board of directors. No more than 33,900,000 shares of Class A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. As of March 31, 2024, there were 4,738,976 shares available for issuance under the 2021 Plan. The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees and directors: Three Months Ended March 31, 2024 2023 Risk-free interest rate 4.1 % 4.2 % Expected term (in years) 6.0 6.0 Expected volatility 49.5 % 47.8 % Expected dividend yield 0 % 0 % Stock options The following table summarizes the Company’s stock option activity since December 31, 2023: Number of Weighted Weighted Aggregate (in years) (in thousands) Outstanding as of December 31, 2023 6,530,511 $ 2.59 7.12 $ — Granted 751,920 0.95 Exercised (20) 0.75 Expired (139,529) 8.08 Forfeited (31,707) 1.28 Outstanding as of March 31, 2024 7,111,175 $ 2.31 7.28 $ 263 Options vested and expected to vest as of March 31, 2024 7,111,175 $ 2.31 7.28 $ 263 Options exercisable as of March 31, 2024 4,003,111 $ 2.60 6.09 $ 180 The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s Class A common stock for those options that had exercise prices lower than such fair value. The intrinsic value of stock options exercised during each of the three months ended March 31, 2024 and 2023 was less than $0.1 million. The weighted average grant-date fair value per share of stock options granted during the three months ended March 31, 2024 and 2023 was $0.50 and $0.63, respectively. Restricted stock units Restricted stock unit grants to employees typically have a three-year service-based vesting term in which vesting occurs annually on the anniversary of the grant date. During the three months ended March 31, 2024, the Company granted restricted stock units with service-based vesting conditions only. The Company expenses the fair value of the restricted stock units over the expected vesting period and accounts for forfeitures prospectively as they occur. The following table summarizes the Company's restricted stock units activity since December 31, 2023: Number of Weighted Unvested as of December 31, 2023 1,681,760 $ 2.28 Granted 420,640 $ 0.95 Vested (263,175) $ 4.39 Forfeited (16,341) $ 2.80 Unvested as of March 31, 2024 1,822,884 $ 1.66 The weighted average grant-date fair value per share of restricted stock units granted during the three months ended March 31, 2024 and 2023 was $0.95 and $1.20, respectively. 2021 Employee Stock Purchase Plan In July 2021, the board of directors adopted, and the Company’s stockholders approved, the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which became effective in connection with the IPO of Class A common stock. The aggregate number of shares of Class A common stock available for issuance under the 2021 ESPP is equal to (i) 400,000 shares and (ii) an annual increase for ten years on the first day of each calendar year beginning on January 1, 2022, equal to the lesser of (A) 1% of the aggregate number of shares of Class A common stock outstanding on the last day of the immediately preceding calendar year and (B) such smaller amount of shares as determined by the board of directors. No more than 6,300,000 shares of Class A common stock may be issued under the 2021 ESPP. Under the 2021 ESPP, eligible employees may purchase shares of the Company’s common stock through payroll deductions of up to 15% of eligible compensation during an offering period. Generally, each offering period will be for 6 months as determined by the Company's board of directors. In no event may an employee purchase more than 100,000 shares per offering period based on the closing price on the first trading date of an offering period or the last trading date of an offering period, or more than $25,000 worth of stock during any calendar year. The purchase price for shares to be purchased under the 2021 ESPP is 85% of the lesser of the market price of the Company's common stock on the first trading date of an offering period or on any purchase date during an offering period (March 14 or September 14). During the three months ended March 31, 2024, there were 198,299 shares of Class A common stock purchased under the 2021 ESPP. The Company recognized less than $0.1 million of expense related to the 2021 ESPP for each of the three months ended March 31, 2024 and 2023. As of March 31, 2024, 1,045,858 shares were available for future issuance under the 2021 ESPP. The Company estimates the fair value of shares issued to employees under the 2021 ESPP using the Black-Scholes option-pricing model. The following weighted average assumptions were used in the calculation of fair value of shares under the 2021 ESPP at the grant date for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, 2024 2023 Risk-free interest rate 5.4 % 4.7 % Expected term (in years) 0.5 0.5 Expected volatility 49.4 % 47.8 % Expected dividend yield 0 % 0 % 2023 Inducement Plan In May 2023, the board of directors adopted the 2023 Inducement Plan (the “Inducement Plan”) pursuant to which the Company reserved 330,000 shares of Class A common stock to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Company as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan provides for the grant of equity-based awards in the form of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and dividend equivalent rights. The Inducement Plan was adopted by the board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In May 2023, pursuant to the Inducement Plan, the Company granted inducement awards to the Company's Senior Vice President, Sales & Marketing, in the form of an option to purchase 220,000 shares of the Company's Class A common stock, with an exercise price per share of $0.83, and 110,000 restricted stock units. The option and restricted stock unit awards were granted as inducements material to the commencement of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). In February 2024, the Company amended its Inducement Plan to reserve an additional 225,000 shares of its Class A common stock. The amendment was adopted by the compensation committee of the board of directors, without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In March 2024, pursuant to the Inducement Plan as amended, the Company granted inducement awards to the Company's Vice President, Legal, in the form of an option to purchase 150,000 shares of the Company's Class A common stock, with an exercise price per share of $0.99, and 75,000 restricted stock units. The option and restricted stock unit awards were granted as inducements material to the commencement of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). As of March 31, 2024, no shares were available for future issuance under the Inducement Plan. Stock-based compensation Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands): Three Months Ended March 31, 2024 2023 Cost of revenue $ 147 $ 174 Research and development 129 157 Sales and marketing 105 131 General and administrative 704 781 Total stock-based compensation expense $ 1,085 $ 1,243 As of March 31, 2024, total unrecognized compensation expense related to unvested stock options held by employees and directors was $3.8 million, which is expected to be recognized over a weighted average period of 1.8 years. Additionally, unrecognized compensation expense related to unvested restricted stock units held by employees and directors was $2.4 million, which is expected to be recognized over a weighted average period of 1.9 years.

Income taxes

Income taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income taxes	Income taxes During the three months ended March 31, 2024 and 2023, the pretax losses incurred by the Company, as well as the research and development tax credits generated, received no corresponding tax benefit because the Company concluded that it is more likely than not that the Company will be unable to realize the value of any resulting deferred tax assets. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance in the future. The Company’s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate, adjusted for the effect of discrete items arising in that quarter. The income tax provision was generated from operations in Germany and Switzerland. The impact of such discrete items could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings or losses versus annual projections. In each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, a cumulative adjustment is made in that quarter. The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, as of March 31, 2024 and December 31, 2023 the Company has recorded a full valuation allowance against its net deferred tax assets. The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by U.S. federal, state and international jurisdictions, where applicable. There are currently no pending tax examinations in the U.S., and the Company has not received notice of examination from any jurisdictions in the U.S.

Net loss per share

Net loss per share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net loss per share	Net loss per share As of March 31, 2024, the Company had Class A common stock and Class B common stock. Both classes have the same rights to the Company’s earnings and neither of the shares have any prior or senior rights to dividends to other shares. Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts): Three Months Ended March 31, 2024 2023 Numerator: Net loss $ (13,322) $ (13,887) Denominator: Weighted average Class A common shares outstanding—basic and diluted 37,936,306 37,259,201 Weighted average Class B common shares outstanding—basic and diluted 5,309,529 5,553,379 Total shares for EPS—basic and diluted 43,245,835 42,812,580 Net loss per share attributable to Class A common stockholders—basic and diluted $ (0.31) $ (0.32) Net loss per share attributable to Class B common stockholders—basic and diluted $ (0.31) $ (0.32) The Company’s potentially dilutive securities, which include stock options, restricted stock, restricted stock units, and common stock warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: March 31, 2024 2023 Options to purchase common stock 7,111,175 6,064,365 Unvested restricted common stock 1,822,884 286,324 Warrants to purchase common stock 286,324 874,714 Options to purchase common stock under ESPP 11,559 5,244 9,231,942 7,230,647

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leases	Leases The Company determines if an arrangement is or contains a lease at inception, which is the date on which the terms of the contract are agreed to, and the agreement creates enforceable rights and obligations. Under ASC 842, a contract is or contains a lease when (i) explicitly or implicitly identified assets have been deployed in the contract and (ii) the customer obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company also considers whether its service arrangements include the right to control the use of an asset. See Note 2 for more information on the Company’s accounting policies for leases. The Company leases office and manufacturing space under operating lease agreements that have initial terms ranging from approximately 8 to 10 years. The Company leases furniture under a financing lease agreement that has an initial term of approximately 8 years. Some leases include one or more options to renew, generally at the Company's sole discretion, with renewal terms that can extend the lease term by up to 5 years. In addition, certain leases contain termination options, where the rights to terminate are held by either the Company, the lessor, or both parties. Options to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise the option. Options to terminate a lease are excluded from the lease term when it is reasonably certain that the Company will not exercise the option. The Company’s leases generally do not contain any material restrictive covenants or residual value guarantees. Supplemental cash flow information related to leases is as follows (in thousands): Three Months Ended March 31, 2024 2023 Cash paid for amounts included in measurement of lease liabilities: Operating cash outflows - payments on operating leases $ 331 $ 316 Operating cash outflows - payments on financing leases $ 9 $ 10 Financing cash outflows - payments on financing leases $ 10 $ 9 Supplemental balance sheet information related to the Company’s operating and financing leases is as follows (in thousands): March 31, 2024 December 31, 2023 Operating Leases: Operating lease assets $ 5,732 $ 5,972 Operating lease liabilities, short-term $ 1,109 $ 1,090 Operating lease liabilities, long-term 5,665 5,952 Total operating lease liabilities $ 6,774 $ 7,042 Financing Leases: Office furniture and fixtures $ 386 $ 386 Accumulated depreciation (130) (118) Net property, plant and equipment $ 256 $ 268 Lease liabilities, short-term $ 43 $ 42 Lease liabilities, long-term 252 262 Total financing lease liabilities $ 295 $ 304 Weighted-average remaining lease term - operating leases (in years): 5.29 5.54 Weighted-average remaining lease term - financing leases (in years): 5.25 5.50 Weighted-average discount rate - operating leases: 3.8 % 3.8 % Weighted-average discount rate - financing leases: 12.0 % 12.0 % The components of lease expense were as follows (in thousands): Three Months Ended March 31, 2024 2023 Operating lease cost $ 305 $ 297 Financing lease cost - amortization of right-of-use asset 12 12 Financing lease cost - interest on lease liability 9 10 Variable lease cost 205 170 Total lease cost $ 531 $ 489 Operating lease cost is recognized on a straight-line basis over the lease term. Total rent expense, including the Company’s share of the lessors’ operating expenses, was $0.5 million for each of the three months ended March 31, 2024 and 2023. Financing lease cost includes asset amortization on a straight-line basis over the lease term and interest accretion calculated using the effective interest method. Total financing lease asset depreciation and interest expense was less than $0.1 million for each of the three months ended March 31, 2024 and 2023. Maturities of the Company’s operating lease liabilities as of March 31, 2024 were as follows (in thousands): Operating Lease Maturities 2024 (excluding the three months ended March 31) $ 1,003 2025 1,368 2026 1,401 2027 1,435 2028 1,468 Thereafter 805 Total lease payments $ 7,480 Less imputed interest (706) Total present value of lease liabilities $ 6,774 Maturities of the Company’s financing lease liability as of March 31, 2024 were as follows (in thousands): Financing Lease Maturities 2024 (excluding the three months ended March 31) $ 56 2025 75 2026 75 2027 75 2028 75 Thereafter 38 Total lease payments $ 394 Less imputed interest (99) Total present value of lease liabilities $ 295
Leases	Leases The Company determines if an arrangement is or contains a lease at inception, which is the date on which the terms of the contract are agreed to, and the agreement creates enforceable rights and obligations. Under ASC 842, a contract is or contains a lease when (i) explicitly or implicitly identified assets have been deployed in the contract and (ii) the customer obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company also considers whether its service arrangements include the right to control the use of an asset. See Note 2 for more information on the Company’s accounting policies for leases. The Company leases office and manufacturing space under operating lease agreements that have initial terms ranging from approximately 8 to 10 years. The Company leases furniture under a financing lease agreement that has an initial term of approximately 8 years. Some leases include one or more options to renew, generally at the Company's sole discretion, with renewal terms that can extend the lease term by up to 5 years. In addition, certain leases contain termination options, where the rights to terminate are held by either the Company, the lessor, or both parties. Options to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise the option. Options to terminate a lease are excluded from the lease term when it is reasonably certain that the Company will not exercise the option. The Company’s leases generally do not contain any material restrictive covenants or residual value guarantees. Supplemental cash flow information related to leases is as follows (in thousands): Three Months Ended March 31, 2024 2023 Cash paid for amounts included in measurement of lease liabilities: Operating cash outflows - payments on operating leases $ 331 $ 316 Operating cash outflows - payments on financing leases $ 9 $ 10 Financing cash outflows - payments on financing leases $ 10 $ 9 Supplemental balance sheet information related to the Company’s operating and financing leases is as follows (in thousands): March 31, 2024 December 31, 2023 Operating Leases: Operating lease assets $ 5,732 $ 5,972 Operating lease liabilities, short-term $ 1,109 $ 1,090 Operating lease liabilities, long-term 5,665 5,952 Total operating lease liabilities $ 6,774 $ 7,042 Financing Leases: Office furniture and fixtures $ 386 $ 386 Accumulated depreciation (130) (118) Net property, plant and equipment $ 256 $ 268 Lease liabilities, short-term $ 43 $ 42 Lease liabilities, long-term 252 262 Total financing lease liabilities $ 295 $ 304 Weighted-average remaining lease term - operating leases (in years): 5.29 5.54 Weighted-average remaining lease term - financing leases (in years): 5.25 5.50 Weighted-average discount rate - operating leases: 3.8 % 3.8 % Weighted-average discount rate - financing leases: 12.0 % 12.0 % The components of lease expense were as follows (in thousands): Three Months Ended March 31, 2024 2023 Operating lease cost $ 305 $ 297 Financing lease cost - amortization of right-of-use asset 12 12 Financing lease cost - interest on lease liability 9 10 Variable lease cost 205 170 Total lease cost $ 531 $ 489 Operating lease cost is recognized on a straight-line basis over the lease term. Total rent expense, including the Company’s share of the lessors’ operating expenses, was $0.5 million for each of the three months ended March 31, 2024 and 2023. Financing lease cost includes asset amortization on a straight-line basis over the lease term and interest accretion calculated using the effective interest method. Total financing lease asset depreciation and interest expense was less than $0.1 million for each of the three months ended March 31, 2024 and 2023. Maturities of the Company’s operating lease liabilities as of March 31, 2024 were as follows (in thousands): Operating Lease Maturities 2024 (excluding the three months ended March 31) $ 1,003 2025 1,368 2026 1,401 2027 1,435 2028 1,468 Thereafter 805 Total lease payments $ 7,480 Less imputed interest (706) Total present value of lease liabilities $ 6,774 Maturities of the Company’s financing lease liability as of March 31, 2024 were as follows (in thousands): Financing Lease Maturities 2024 (excluding the three months ended March 31) $ 56 2025 75 2026 75 2027 75 2028 75 Thereafter 38 Total lease payments $ 394 Less imputed interest (99) Total present value of lease liabilities $ 295

Commitments and contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Indemnification agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to customers, vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and certain of its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March 31, 2024 and December 31, 2023. Legal proceedings The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to legal proceedings.

Benefit plans

Benefit plans	3 Months Ended
	Mar. 31, 2024
Retirement Benefits [Abstract]
Benefit plans	Benefit plansThe Company maintains a defined contribution savings plan under Section 401(k) of the Code. This plan covers all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the plan may be made at the discretion of the Company’s board of directors. The Company made contributions of $0.3 million and $0.2 million to the plan during the three months ended March 31, 2024 and 2023, respectively.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net loss	$ (13,322)	$ (13,887)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation These condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries in Germany and Switzerland. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s audited consolidated financial statements for the year ended December 31, 2023. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2024 and the results of its operations and its cash flows for the three months ended March 31, 2024 and 2023. The financial data and other information disclosed in these notes related to the three months ended March 31, 2024 and 2023 are also unaudited. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period.
Use of estimates	Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, calculating the standalone selling price for revenue recognition, the valuation of inventory, and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific and relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Risk of concentrations of credit, significant customers and significant suppliers	Risk of concentrations of credit, significant customers and significant suppliers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments and accounts receivable. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash and cash equivalents and investments with financial institutions that management believes to be of high credit quality. The Company has not experienced any other-than-temporary losses with respect to its cash equivalents and investments and does not believe that it is subject to unusual credit risk beyond the credit risk associated with commercial banking relationships.
Cash and cash equivalents	Cash and cash equivalents
Restricted cash	Restricted cash As of both March 31, 2024 and December 31, 2023, the Company was required to maintain guaranteed investment certificates of $0.3 million with maturities of three months to one year that are subject to an insignificant risk of changes in value. The guaranteed investment certificates are held for the benefit of the landlord in connection with operating leases which have remaining terms of greater than one year and are classified as restricted cash (non-current) on the Company’s consolidated balance sheets.
Software Development Costs	Software Development Costs The Company accounts for software development costs for internal-use software under the provisions of ASC 350-40, “Internal-Use Software
Fair value measurements	Fair value measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company’s cash equivalents, short-term and long-term investments are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.
Product warranties	Product warranties
Segment information	Segment information The Company determined its operating segment after considering the Company’s organizational structure and the information regularly reviewed and evaluated by the Company’s chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company has determined that its CODM is its Chief Executive Officer. The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. On the basis of these factors, the Company determined that it operates and manages its business as one operating segment, that develops, manufactures, markets and sells Systems and related LIMS connection software, consumables and services; and accordingly has one reportable segment for financial reporting purposes. Substantially all of the Company’s long-lived assets are held in the United States.
Revenue recognition	Revenue recognition Remaining performance obligations The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. The Company does not have material remaining performance obligations associated with contracts with terms greater than one year. Contract balances from contracts with customers Contract assets arise from customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company’s right to payment is conditional and not only subject to the passage of time. The Company had $0.1 million in contract assets as of both March 31, 2024 and December 31, 2023, included in prepaid expenses and other current assets. Contract liabilities represent the Company’s obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. The Company has a contract liability related to service revenue, which consists of amounts that have been invoiced but that have not been recognized as revenue. Amounts expected to be recognized as revenue within 12 months of the balance sheet date are classified as current deferred revenue and amounts expected to be recognized as revenue beyond 12 months of the balance sheet date are classified as non-current deferred revenue. The Company did not record any non-current deferred revenue as of March 31, 2024 or December 31, 2023. Deferred revenue was $6.2 million and $6.0 million at March 31, 2024 and December 31, 2023, respectively. Revenue recognized during the three months ended March 31, 2024 and 2023 that was included in deferred revenue at the prior period-end was $1.4 million and $1.0 million, respectively. Disaggregated revenue
Advertising costs	Advertising costs
Stock-based compensation	Stock-based compensation The Company measures all stock-based awards granted to employees, officers and directors based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company issues stock-based awards with (i) service-based vesting conditions only and (ii) stock-based awards with both service-based and Company performance vesting conditions, and records the expense for these awards using the straight-line method. Forfeitures are accounted for prospectively as they occur.
Recently issued accounting pronouncements	Recently issued accounting pronouncements The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups ("JOBS") Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the newer revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic companies. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. The new standard requires enhanced disclosures about a public entity's reportable segments including more detailed information about a reportable segment's expenses. The amendments in this update apply to all public entities that are required to report segment information, and include those entities that have a single reportable segment. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this update are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of Concentration Risk	The following table presents customers that represented 10% or more of the Company’s total revenue: Three Months Ended March 31, 2024 2023 Customer A 19.4 % 20.1 % Customer B 14.3 % 27.0 % 33.7 % 47.1 % The following table presents customers that represented 10% or more of the Company’s accounts receivable: March 31, December 31, 2024 2023 Customer B 41.9 % 16.4 % Customer A 13.5 % 10.7 % Customer C * 21.4 % Customer D * 12.4 % 55.4 % 60.9 % ____________________________ * – less than 10%
Schedule of Product Warranties	The following table presents a summary of changes in the amount reserved for warranty cost (in thousands): Three Months Ended March 31, 2024 2023 Balance, beginning of period $ 689 $ 872 Warranty provisions — — Warranty repairs — (346) Balance, end of period $ 689 $ 526
Schedule of Disaggregated Revenue	The following table presents the Company’s revenue by the recurring or non-recurring nature of the revenue stream (in thousands): Three Months Ended March 31, 2024 2023 Product and service revenue — recurring $ 3,743 $ 3,253 Product and service revenue — non-recurring 1,868 1,782 Total revenue $ 5,611 $ 5,035 The following table presents the Company’s revenue by customer geography (in thousands): Three Months Ended March 31, 2024 2023 United States $ 2,149 $ 1,703 Switzerland 972 973 Japan 800 1,386 Germany 464 413 All other countries 1,226 560 Total revenue $ 5,611 $ 5,035

Fair value of financial asset_2

Fair value of financial assets and liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured on a Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands): Fair value measurements as of March 31, 2024 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 19,346 $ — $ — $ 19,346 Short-term investments 52,923 4,180 — 57,103 $ 72,269 $ 4,180 $ — $ 76,449 Fair value measurements as of December 31, 2023 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 20,306 $ — $ — $ 20,306 Short-term investments 62,625 5,143 — 67,768 Long-term investments 2,911 — — 2,911 $ 85,842 $ 5,143 $ — $ 90,985

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Investments	Short-term and long-term investments by investment type consisted of the following (in thousands): March 31, 2024 Amortized Gross Gross Fair Short-term investments Certificates of Deposit $ 4,192 $ — $ (11) $ 4,181 U.S. Government Treasury Bills 14,795 — (6) 14,789 U.S. Government Treasury Notes 38,194 3 (64) 38,133 $ 57,181 $ 3 $ (81) $ 57,103 December 31, 2023 Amortized Gross Gross Fair Short-term investments Certificates of Deposit $ 5,164 $ — $ (21) $ 5,143 U.S. Government Treasury Bills 16,184 9 — 16,193 U.S. Government Treasury Notes 46,536 42 (146) 46,432 $ 67,884 $ 51 $ (167) $ 67,768 Long-term Investments U.S. Government Treasury Notes - Maturity Up To Two Years 2,896 15 — 2,911 $ 2,896 $ 15 $ — $ 2,911

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following (in thousands): March 31, December 31, 2024 2023 Raw materials $ 11,654 $ 12,873 Work in process 423 150 Finished goods 8,341 6,938 Total $ 20,418 $ 19,961

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	3 Months Ended
	Mar. 31, 2024
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): March 31, December 31, 2024 2023 Prepaid insurance $ 803 $ 1,282 Contract asset 94 51 Deposits 742 667 Other receivables 333 137 Prepaid financing fees 295 292 Other 1,018 440 $ 3,285 $ 2,869

Property and equipment, net (Ta

Property and equipment, net (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consisted of the following (in thousands): March 31, December 31, 2024 2023 Manufacturing and laboratory equipment $ 13,850 $ 13,750 Computer hardware and software 2,034 1,960 Office furniture and fixtures 589 589 Leasehold improvements 8,995 8,551 Construction-in-process 2,165 2,292 27,633 27,142 Less: Accumulated depreciation (15,018) (14,310) $ 12,615 $ 12,832

Accrued expenses and other cu_2

Accrued expenses and other current liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following (in thousands): March 31, December 31, 2024 2023 Accrued employee compensation and benefits expense $ 2,779 $ 4,808 Accrued vendor expenses 3,198 4,017 Accrued warranty expense 689 689 Accrued taxes 259 252 Other 124 141 $ 7,049 $ 9,907

Common stock and common stock_2

Common stock and common stock warrants (Tables)	3 Months Ended
	Mar. 31, 2024
Common stock and common stock warrants
Schedule of Outstanding Common Stock Warrants	As of both March 31, 2024 and December 31, 2023, outstanding warrants to purchase common stock consisted of the following: Issuance date Contractual term Balance sheet Shares of Weighted average (in years) July 24, 2017 10 Equity 17,194 $ 292.81 April 12, 2018 10 Equity 30,000 $ 1.00 July 14, 2021 * 10 Equity 975,109 $ 1.46 1,022,303 ____________________________ * – In connection with the IPO, preferred stock warrants were automatically converted to Class A common stock warrants. The contractual term of the converted Class A common stock warrants remained consistent with the original term of the preferred stock warrants, with original issue dates between 2017-2020.

Stock-based compensation (Table

Stock-based compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Black-Scholes Option-Pricing Model	The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees and directors: Three Months Ended March 31, 2024 2023 Risk-free interest rate 4.1 % 4.2 % Expected term (in years) 6.0 6.0 Expected volatility 49.5 % 47.8 % Expected dividend yield 0 % 0 %
Schedule of Stock Option Activity	The following table summarizes the Company’s stock option activity since December 31, 2023: Number of Weighted Weighted Aggregate (in years) (in thousands) Outstanding as of December 31, 2023 6,530,511 $ 2.59 7.12 $ — Granted 751,920 0.95 Exercised (20) 0.75 Expired (139,529) 8.08 Forfeited (31,707) 1.28 Outstanding as of March 31, 2024 7,111,175 $ 2.31 7.28 $ 263 Options vested and expected to vest as of March 31, 2024 7,111,175 $ 2.31 7.28 $ 263 Options exercisable as of March 31, 2024 4,003,111 $ 2.60 6.09 $ 180
Schedule of Restricted Stock and Restricted Stock Units Activity	The following table summarizes the Company's restricted stock units activity since December 31, 2023: Number of Weighted Unvested as of December 31, 2023 1,681,760 $ 2.28 Granted 420,640 $ 0.95 Vested (263,175) $ 4.39 Forfeited (16,341) $ 2.80 Unvested as of March 31, 2024 1,822,884 $ 1.66
Schedule of ESPP Black-Scholes Option-Pricing Model	The following weighted average assumptions were used in the calculation of fair value of shares under the 2021 ESPP at the grant date for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, 2024 2023 Risk-free interest rate 5.4 % 4.7 % Expected term (in years) 0.5 0.5 Expected volatility 49.4 % 47.8 % Expected dividend yield 0 % 0 %
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands): Three Months Ended March 31, 2024 2023 Cost of revenue $ 147 $ 174 Research and development 129 157 Sales and marketing 105 131 General and administrative 704 781 Total stock-based compensation expense $ 1,085 $ 1,243

Net loss per share (Tables)

Net loss per share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss per Share	Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts): Three Months Ended March 31, 2024 2023 Numerator: Net loss $ (13,322) $ (13,887) Denominator: Weighted average Class A common shares outstanding—basic and diluted 37,936,306 37,259,201 Weighted average Class B common shares outstanding—basic and diluted 5,309,529 5,553,379 Total shares for EPS—basic and diluted 43,245,835 42,812,580 Net loss per share attributable to Class A common stockholders—basic and diluted $ (0.31) $ (0.32) Net loss per share attributable to Class B common stockholders—basic and diluted $ (0.31) $ (0.32)
Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Let per Share	The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: March 31, 2024 2023 Options to purchase common stock 7,111,175 6,064,365 Unvested restricted common stock 1,822,884 286,324 Warrants to purchase common stock 286,324 874,714 Options to purchase common stock under ESPP 11,559 5,244 9,231,942 7,230,647

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Supplemental Cash Flow Information and Lease Expense	Supplemental cash flow information related to leases is as follows (in thousands): Three Months Ended March 31, 2024 2023 Cash paid for amounts included in measurement of lease liabilities: Operating cash outflows - payments on operating leases $ 331 $ 316 Operating cash outflows - payments on financing leases $ 9 $ 10 Financing cash outflows - payments on financing leases $ 10 $ 9 The components of lease expense were as follows (in thousands): Three Months Ended March 31, 2024 2023 Operating lease cost $ 305 $ 297 Financing lease cost - amortization of right-of-use asset 12 12 Financing lease cost - interest on lease liability 9 10 Variable lease cost 205 170 Total lease cost $ 531 $ 489
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to the Company’s operating and financing leases is as follows (in thousands): March 31, 2024 December 31, 2023 Operating Leases: Operating lease assets $ 5,732 $ 5,972 Operating lease liabilities, short-term $ 1,109 $ 1,090 Operating lease liabilities, long-term 5,665 5,952 Total operating lease liabilities $ 6,774 $ 7,042 Financing Leases: Office furniture and fixtures $ 386 $ 386 Accumulated depreciation (130) (118) Net property, plant and equipment $ 256 $ 268 Lease liabilities, short-term $ 43 $ 42 Lease liabilities, long-term 252 262 Total financing lease liabilities $ 295 $ 304 Weighted-average remaining lease term - operating leases (in years): 5.29 5.54 Weighted-average remaining lease term - financing leases (in years): 5.25 5.50 Weighted-average discount rate - operating leases: 3.8 % 3.8 % Weighted-average discount rate - financing leases: 12.0 % 12.0 %
Schedule of Operating Lease Liability Maturities	Maturities of the Company’s operating lease liabilities as of March 31, 2024 were as follows (in thousands): Operating Lease Maturities 2024 (excluding the three months ended March 31) $ 1,003 2025 1,368 2026 1,401 2027 1,435 2028 1,468 Thereafter 805 Total lease payments $ 7,480 Less imputed interest (706) Total present value of lease liabilities $ 6,774
Schedule of Finance Lease Liability Maturities	Maturities of the Company’s financing lease liability as of March 31, 2024 were as follows (in thousands): Financing Lease Maturities 2024 (excluding the three months ended March 31) $ 56 2025 75 2026 75 2027 75 2028 75 Thereafter 38 Total lease payments $ 394 Less imputed interest (99) Total present value of lease liabilities $ 295

Summary of significant accoun_4

Summary of significant accounting policies - Schedule of Concentration Risk (Details) - Customer Concentration Risk	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Revenue Benchmark | Major Customers
Concentration Risk [Line Items]
Customer concentration risk	33.70%	47.10%
Revenue Benchmark | Customer A
Concentration Risk [Line Items]
Customer concentration risk	19.40%	20.10%
Revenue Benchmark | Customer B
Concentration Risk [Line Items]
Customer concentration risk	14.30%	27%
Accounts Receivable | Major Customers
Concentration Risk [Line Items]
Customer concentration risk	55.40%		60.90%
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Customer concentration risk	13.50%		10.70%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Customer concentration risk	41.90%		16.40%
Accounts Receivable | Customer C
Concentration Risk [Line Items]
Customer concentration risk			21.40%
Accounts Receivable | Customer D
Concentration Risk [Line Items]
Customer concentration risk			12.40%

Summary of significant accoun_5

Summary of significant accounting policies - Narrative (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) segment	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)
Accounting Policies [Line Items]
Cash held in banks outside of the US	$ 100,000		$ 100,000
Guaranteed investment certificates	284,000		284,000
Software development costs, net of amortization	1,400,000		1,400,000
Amortization of software development costs	800,000		700,000
Software development amortization expense	$ 100,000	$ 100,000
Product warranty term	1 year
Number of operating segments | segment	1
Number of reportable segments | segment	1
Contract assets	$ 100,000		100,000
Non-current deferred revenue	0		0
Current deferred revenue	6,234,000		$ 5,974,000
Revenue recognized which was included in deferred revenue in prior period	1,400,000	1,000,000
Advertising costs	$ 100,000	$ 100,000
Software Development
Accounting Policies [Line Items]
Amortization period of capitalized software costs	5 years

Summary of significant accoun_6

Summary of significant accounting policies - Schedule of Product Warranties (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at beginning of period	$ 689	$ 872
Warranty provisions	0	0
Warranty repairs	0	(346)
Balance at end of period	$ 689	$ 526

Summary of significant accoun_7

Summary of significant accounting policies - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 5,611	$ 5,035
United States
Disaggregation of Revenue [Line Items]
Total revenue	2,149	1,703
Switzerland
Disaggregation of Revenue [Line Items]
Total revenue	972	973
Japan
Disaggregation of Revenue [Line Items]
Total revenue	800	1,386
Germany
Disaggregation of Revenue [Line Items]
Total revenue	464	413
All other countries
Disaggregation of Revenue [Line Items]
Total revenue	1,226	560
Product and Service Revenue | Recurring
Disaggregation of Revenue [Line Items]
Total revenue	3,743	3,253
Product and Service Revenue | Non-recurring
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,868	$ 1,782

Fair value of financial asset_3

Fair value of financial assets and liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	$ 57,103	$ 67,768
Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		2,911
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	19,346	20,306
Assets	76,449	90,985
Fair Value, Recurring | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	57,103	67,768
Fair Value, Recurring | Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		2,911
Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	19,346	20,306
Assets	72,269	85,842
Fair Value, Recurring | Level 1 | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	52,923	62,625
Fair Value, Recurring | Level 1 | Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		2,911
Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Assets	4,180	5,143
Fair Value, Recurring | Level 2 | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	4,180	5,143
Fair Value, Recurring | Level 2 | Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		0
Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Assets	0	0
Fair Value, Recurring | Level 3 | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	$ 0	0
Fair Value, Recurring | Level 3 | Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		$ 0

Investments (Details)

Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Short-term investments
Debt Securities, Available-for-sale [Line Items]
Amortized cost	$ 57,181	$ 67,884
Gross unrealized gains	3	51
Gross unrealized losses	(81)	(167)
Fair value	57,103	67,768
Certificates of Deposit
Debt Securities, Available-for-sale [Line Items]
Amortized cost	4,192	5,164
Gross unrealized gains	0	0
Gross unrealized losses	(11)	(21)
Fair value	4,181	5,143
U.S. Government Treasury Bills
Debt Securities, Available-for-sale [Line Items]
Amortized cost	14,795	16,184
Gross unrealized gains	0	9
Gross unrealized losses	(6)	0
Fair value	14,789	16,193
U.S. Government Treasury Notes
Debt Securities, Available-for-sale [Line Items]
Amortized cost	38,194	46,536
Gross unrealized gains	3	42
Gross unrealized losses	(64)	(146)
Fair value	$ 38,133	46,432
Long-term Investments
Debt Securities, Available-for-sale [Line Items]
Amortized cost		2,896
Gross unrealized gains		15
Gross unrealized losses		0
Fair value		2,911
U.S. Government Treasury Notes - Maturity Between One and Two Years
Debt Securities, Available-for-sale [Line Items]
Amortized cost		2,896
Gross unrealized gains		15
Gross unrealized losses		0
Fair value		$ 2,911

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 11,654	$ 12,873
Work in process	423	150
Finished goods	8,341	6,938
Total	20,418	19,961
Inventory adjustments	$ 700	$ 600

Prepaid expenses and other cu_3

Prepaid expenses and other current assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid insurance	$ 803	$ 1,282
Contract asset	94	51
Deposits	742	667
Other receivables	333	137
Prepaid financing fees	295	292
Other	1,018	440
Prepaid expenses and other current assets	$ 3,285	$ 2,869

Property and equipment, net - S

Property and equipment, net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 27,633	$ 27,142
Less: Accumulated depreciation	(15,018)	(14,310)
Property plant and equipment, net	12,615	12,832
Manufacturing and laboratory equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	13,850	13,750
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	2,034	1,960
Office furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	589	589
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	8,995	8,551
Construction-in-process
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 2,165	$ 2,292

Property and equipment, net - N

Property and equipment, net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 0.7	$ 0.7

Accrued expenses and other cu_3

Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued employee compensation and benefits expense	$ 2,779	$ 4,808
Accrued vendor expenses	3,198	4,017
Accrued warranty expense	689	689
Accrued taxes	259	252
Other	124	141
Total accrued expenses and other current liabilities	$ 7,049	$ 9,907

Common stock and common stock_3

Common stock and common stock warrants - Narrative (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) vote shares	Dec. 31, 2023 vote
Common stock and common stock warrants
Cash dividends | $	$ 0
Class A Common stock
Common stock and common stock warrants
Number of votes per share held | vote	1	1
Shares reserved (in shares) | shares	24,147,346

Common stock and common stock_4

Common stock and common stock warrants - Schedule of Outstanding Common Stock Warrants (Details) - Common Stock Warrants - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Common stock and common stock warrants
Shares of common stock issuable upon exercise of warrant (in shares)	1,022,303	1,022,303
July 24, 2017
Common stock and common stock warrants
Contractual term	10 years	10 years
Shares of common stock issuable upon exercise of warrant (in shares)	17,194	17,194
Weighted average exercise price (in dollars per share)	$ 292.81	$ 292.81
April 12, 2018
Common stock and common stock warrants
Contractual term	10 years	10 years
Shares of common stock issuable upon exercise of warrant (in shares)	30,000	30,000
Weighted average exercise price (in dollars per share)	$ 1	$ 1
July 14, 2021
Common stock and common stock warrants
Contractual term	10 years	10 years
Shares of common stock issuable upon exercise of warrant (in shares)	975,109	975,109
Weighted average exercise price (in dollars per share)	$ 1.46	$ 1.46

Stock-based compensation - Narr

Stock-based compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended
	Mar. 31, 2024	Feb. 29, 2024	May 31, 2023	Jul. 31, 2021	Mar. 31, 2024	Mar. 31, 2023
Share-based compensation
Intrinsic value of stock options exercised					$ 100	$ 100
Weighted average grant-date fair value of stock options granted (in dollars per share)					$ 0.50	$ 0.63
Stock-based compensation expense					$ 1,085	$ 1,243
Options granted (in shares)					751,920
Granted (in dollars per share)					$ 0.95
Unrecognized compensation expense	$ 3,800				$ 3,800
Restricted Stock Units (RSUs)
Share-based compensation
Units granted (in shares)					420,640
Vesting Period					3 years
Weighted average grant-date fair value per share of units granted (in dollars per share)					$ 0.95	$ 1.20
Weighted average recognition period					1 year 10 months 24 days
Unrecognized compensation expense related to units	$ 2,400				$ 2,400
Share-Based Payment Arrangement, Option
Share-based compensation
Weighted average recognition period					1 year 9 months 18 days
Class A Common stock
Share-based compensation
Shares available for future issuance (in shares)	24,147,346				24,147,346
2010 Plan
Share-based compensation
Shares authorized (in shares)	0				0
2021 Plan
Share-based compensation
Shares authorized (in shares)	4,738,976				4,738,976
Plan term				10 years
2021 Plan | Class A Common stock
Share-based compensation
Shares authorized (in shares)				4,200,000
Percentage of aggregate number of shares outstanding				5%
Maximum number of shares issuable upon exercise of stock option (in shares)				33,900,000
2021 ESPP
Share-based compensation
Plan term				10 years
Stock-based compensation expense					$ 100	$ 100
2021 ESPP | Employee Stock
Share-based compensation
Maximum percentage of payroll deduction				15%
Offering period				6 months
Maximum shares available for purchase per employee (in shares)				100,000
Maximum value of shares available for purchase per employee				$ 25
Discount percentage from market price				85%
2021 ESPP | Class A Common stock
Share-based compensation
Shares authorized (in shares)				400,000
Percentage of aggregate number of shares outstanding				1%
Maximum number of shares issuable upon exercise of stock option (in shares)				6,300,000
Shares purchased under plan (in shares)					198,299
Shares available for future issuance (in shares)	1,045,858				1,045,858
Inducement Plan
Share-based compensation
Options granted (in shares)			220,000
Granted (in dollars per share)			$ 0.83
Shares available for issuance under plan (in shares)	0				0
Inducement Plan | Vice President, Legal
Share-based compensation
Options granted (in shares)	150,000
Granted (in dollars per share)	$ 0.99
Inducement Plan | Restricted Stock Units (RSUs)
Share-based compensation
Units granted (in shares)			110,000
Inducement Plan | Restricted Stock Units (RSUs) | Vice President, Legal
Share-based compensation
Units granted (in shares)	75,000
Inducement Plan | Class A Common stock
Share-based compensation
Shares available for future issuance (in shares)			330,000
Additional shares authorized (in shares)		225,000

Stock-based compensation - Sche

Stock-based compensation - Schedule of Black-Scholes Option-Pricing Model (Details) - Share-Based Payment Arrangement, Option - 2021 Plan	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based compensation
Risk-free interest rate	4.10%	4.20%
Expected term (in years)	6 years	6 years
Expected volatility	49.50%	47.80%
Expected dividend yield	0%	0%

Stock-based compensation - Stoc

Stock-based compensation - Stock Option Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Number of shares
Outstanding at beginning of period (in shares) | shares	6,530,511
Granted (in shares) | shares	751,920
Exercised (in shares) | shares	(20)
Expired (in shares) | shares	(139,529)
Forfeited (in shares) | shares	(31,707)
Outstanding at end of period (in shares) | shares	7,111,175	6,530,511
Options vested and expected to vest (in shares) | shares	7,111,175
Options exercisable (in shares) | shares	4,003,111
Weighted average exercise price
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 2.59
Options granted (in dollars per share) | $ / shares	0.95
Exercised (in dollars per share) | $ / shares	0.75
Expired (in dollars per share) | $ / shares	8.08
Forfeited (in dollars per share) | $ / shares	1.28
Outstanding at end of period (in dollars per share) | $ / shares	2.31	$ 2.59
Options vested and expected to vest (in dollars per share) | $ / shares	2.31
Options exercisable (in dollars per share) | $ / shares	$ 2.60
Weighted average remaining contractual term
Weighted average remaining contractual term of options outstanding	7 years 3 months 10 days	7 years 1 month 13 days
Weighted average remaining contractual term of options vested and expected to vest	7 years 3 months 10 days
Weighted average remaining contractual term of options exercisable	6 years 1 month 2 days
Aggregate intrinsic value
Aggregate intrinsic value of options outstanding | $	$ 263	$ 0
Aggregate intrinsic value of options vested and expected to vest | $	263
Aggregate intrinsic value of options exercisable | $	$ 180

Stock-based compensation - Sc_2

Stock-based compensation - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Number of shares
Unvested units at beginning of period (in shares)	1,681,760
Granted (in shares)	420,640
Vested (in shares)	(263,175)
Forfeited (in shares)	(16,341)
Unvested units at end of period (in shares)	1,822,884
Weighted average fair value
Unvested units at beginning of period (in dollars per share)	$ 2.28
Granted (in dollars per share)	0.95	$ 1.20
Vested (in dollars per share)	4.39
Forfeited (in dollars per shares)	2.80
Unvested units at end of period (in dollars per share)	$ 1.66

Stock-based compensation - Sc_3

Stock-based compensation - Schedule of ESPP Black-Scholes Option-Pricing Model (Details) - Employee Stock - 2021 ESPP	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based compensation
Risk-free interest rate	5.40%	4.70%
Expected term (in years)	6 months	6 months
Expected volatility	49.40%	47.80%
Expected dividend yield	0%	0%

Stock-based compensation - Sc_4

Stock-based compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,085	$ 1,243
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	147	174
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	129	157
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	105	131
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 704	$ 781

Net loss per share - Basic and

Net loss per share - Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net loss	$ (13,322)	$ (13,887)
Denominator:
Weighted average common shares outstanding - basic (in shares)	43,245,835	42,812,580
Weighted average common shares outstanding - diluted (in shares)	43,245,835	42,812,580
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (0.31)	$ (0.32)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (0.31)	$ (0.32)
Class A Common stock
Denominator:
Weighted average common shares outstanding - basic (in shares)	37,936,306	37,259,201
Weighted average common shares outstanding - diluted (in shares)	37,936,306	37,259,201
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (0.31)	$ (0.32)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (0.31)	$ (0.32)
Class B Common stock
Denominator:
Weighted average common shares outstanding - basic (in shares)	5,309,529	5,553,379
Weighted average common shares outstanding - diluted (in shares)	5,309,529	5,553,379
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (0.31)	$ (0.32)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (0.31)	$ (0.32)

Net loss per share - Schedule o

Net loss per share - Schedule of Anti-Dilutive Shares Excluded from Computation of Diluted Net Let per Share (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	9,231,942	7,230,647
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	7,111,175	6,064,365
Unvested restricted common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	1,822,884	286,324
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	286,324	874,714
Options to purchase common stock under ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from computation of diluted net loss per share attributable to common stockholders (in shares)	11,559	5,244

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) renewal_option	Mar. 31, 2023 USD ($)
Leases
Finance lease term	8 years
Finance lease renewal term	5 years
Rent expense	$ 0.5	$ 0.5
Depreciation and interest expense	$ 0.1	$ 0.1
Minimum
Leases
Operating lease term	8 years
Number of finance lease renew options | renewal_option	1
Maximum
Leases
Operating lease term	10 years

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash paid for amounts included in measurement of lease liabilities:
Operating cash outflows - payments on operating leases	$ 331	$ 316
Operating cash outflows - payments on financing leases	9	10
Financing cash outflows - payments on financing leases	$ 10	$ 9

Leases - Schedule of Suppleme_2

Leases - Schedule of Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Operating Leases:
Operating lease assets	$ 5,732	$ 5,972
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Right-of-use assets, net	Right-of-use assets, net
Operating lease liabilities, short-term	$ 1,109	$ 1,090
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, short-term	Lease liabilities, short-term
Operating lease liabilities, long-term	$ 5,665	$ 5,952
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, long-term	Lease liabilities, long-term
Total operating lease liabilities	$ 6,774	$ 7,042
Financing Leases:
Office furniture and fixtures	386	386
Accumulated depreciation	(130)	(118)
Net property, plant and equipment	$ 256	$ 268
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Right-of-use assets, net	Right-of-use assets, net
Lease liabilities, short-term	$ 43	$ 42
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, short-term	Lease liabilities, short-term
Lease liabilities, long-term	$ 252	$ 262
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, long-term	Lease liabilities, long-term
Total financing lease liabilities	$ 295	$ 304
Weighted-average remaining lease term - operating leases (in years):	5 years 3 months 14 days	5 years 6 months 14 days
Weighted-average remaining lease term - financing leases (in years):	5 years 3 months	5 years 6 months
Weighted-average discount rate - operating leases:	3.80%	3.80%
Weighted-average discount rate - financing leases:	12%	12%

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Operating lease cost	$ 305	$ 297
Financing lease cost - amortization of right-of-use asset	12	12
Financing lease cost - interest on lease liability	9	10
Variable lease cost	205	170
Total lease cost	$ 531	$ 489

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Liability Maturities (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Leases [Abstract]
2024 (excluding the three months ended March 31)	$ 1,003
2025	1,368
2026	1,401
2027	1,435
2028	1,468
Thereafter	805
Total lease payments	7,480
Less imputed interest	(706)
Total present value of lease liabilities	$ 6,774

Leases - Schedule of Finance Le

Leases - Schedule of Finance Lease Liability Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Leases [Abstract]
2024 (excluding the three months ended March 31)	$ 56
2025	75
2026	75
2027	75
2028	75
Thereafter	38
Total lease payments	394
Less imputed interest	(99)
Total present value of lease liabilities	$ 295	$ 304

Benefit plans (Details)

Benefit plans (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Retirement Benefits [Abstract]
Company contributions to plan	$ 0.3	$ 0.2